Prospects in the pharmacotherapy of type 2 diabetes for the next 10 years

[en] Type 2 diabetes (T2D) is a complex disease characterized by different pathophysiological mechanisms. None of the available antidiabetic agents is able to target all the underlying abnormalities so that combined therapies are often mandatory. Despite that, numerous patients remain with a poorly controlled T2D, which exposes them to an increased risk of vascular complications. New glucose-lowering compounds are currently in development by the pharmaceutical industry in preclinical or already clinical phases. Some belong to well-known pharmacological classes and should be commercialized in a rather near future. Other combine different approaches that are potentially complementary, either as fixed-dose combinations or with original molecules that exert double, or even triple, activities. While new insulin secretagogues are investigated, an increasing interest is focusing on glucagon. This review describes novel antidiabetic agents at different phases of development: delayed-release metformin, new PPAR agonists, GLP-1 receptor agonists, co-agonists of GLP-1/GIP/glucagon receptors, SGLT2/SGLT1 inhibitors, new insulin-secreting compounds, antagonists of glucagon receptors, anti-obesity agents, innovative anti-inflammatory compounds. If some of these new antidiabetic medications arrive on the market within the next 10 years, they should demonstrate an added value compared to already available glucose-lowering agents, be at best integrated within the therapeutic algorithms, and have a reasonable prize allowing reimbursement. © 2018 Elsevier Masson SAS

Disciplines :

Pharmacy, pharmacology & toxicology
Endocrinology, metabolism & nutrition

Author, co-author :

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques

Language :

English

Title :

Prospects in the pharmacotherapy of type 2 diabetes for the next 10 years

Alternative titles :

[fr] Perspectives dans le traitement pharmacologique du diabète de type 2 pour les 10 prochaines années

Publication date :

2018

Journal title :

Médecine des Maladies Métaboliques

ISSN :

1957-2557

eISSN :

2214-8477

Publisher :

Elsevier Masson

Volume :

Issue :

Pages :

174-181

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 19 October 2021

Statistics

Number of views

56 (2 by ULiège)

Number of downloads

125 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Scheen, A.J., Antidiabétiques oraux dans le traitement du diabète de type 2 : perspectives historique et médico-économique. Médecine des maladies Métaboliques 9 (2015), 186–197.
Scheen, A.J., Pharmacological management of type 2 diabetes: what's new in 2017?. Expert Rev Clin Pharmacol 10 (2017), 1383–1394.
Tahrani, A.A., Barnett, A.H., Bailey, C.J., Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nat Rev Endocrinol 12 (2016), 566–592.
Scheen, A.J., Pharmacotherapy of ‘treatment resistant’ type 2 diabetes. Expert Opin Pharmacother 18 (2017), 503–515.
Scheen, A.J., ‘Treatment-resistant’ type 2 diabetes: Which definition for clinical practice?. Diabetes Metab 43 (2017), 295–297.
Bailey, C.J., Tahrani, A.A., Barnett, A.H., Future glucose-lowering drugs for type 2 diabetes. Lancet Diabetes Endocrinol 4 (2016), 350–359.
Kumar, A., Bharti, S.K., Kumar, A., Therapeutic molecules against type 2 diabetes: What we have and what are we expecting?. Pharmacol Rep 69 (2017), 959–970.
Clemmensen, C., Müller, T.D., Finan, B., et al. Current and emerging treatment options in diabetes care. Handb Exp Pharmacol 233 (2016), 437–459.
Scheen, A.J., Historique des études cardiovasculaires : de l'UGDP … aux dernières études. Médecine des maladies Métaboliques 11:Suppl.2 (2017), 215–226.
Darmon, P., Bauduceau, B., Bordier, L., et al. Société Francophone du Diabète (SFD). Prise de position de la Société Francophone du Diabète (SFD) sur la prise en charge médicamenteuse de l'hyperglycémie du patient diabétique de type 2. Médecine des maladies Métaboliques 11 (2017), 577–593.
Bonnet, F., Scheen, A., Understanding and overcoming metformin gastrointestinal intolerance. Diabetes Obes Metab 19 (2017), 473–481.
Scheen, A.J., Paquot, N., Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. Diabetes Metab 39 (2013), 179–190.
Scheen, A.J., Comment je traite.. par metformine un patient diabétique avec insuffisance rénale modérée. Rev Med Liege 68 (2013), 190–195.
Buse, J.B., DeFronzo, R.A., Rosenstock, J., et al. The primary glucose-lowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacokinetic and 12-week doseranging studies. Diabetes Care 39 (2016), 198–205.
DeFronzo, R.A., Buse, J.B., Kim, T., et al. Oncedaily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials. Diabetologia 59 (2016), 1645–1654.
Scheen, A.J., Will delayed release metformin provide better management of diabetes type 2?. Expert Opin Pharmacother 17 (2016), 627–630.
Scheen, A.J., Personalising metformin therapy: a clinician's perspective. Lancet Diabetes Endocrinol 2 (2014), 442–444.
Scheen, A.J., DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects. Expert Opin Drug Metab Toxicol 12 (2016), 1407–1417.
Scheen, A.J., Paquot, N., Combinaison gliptinegliflozine dans le traitement du diabète de type 2. Rev Med Suisse 12 (2016), 1384–1388.
Scheen, A.J., Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol 13 (2017), 583–592.
Rizos, C.V., Filippatos, T.D., Elisaf, M.S., Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol 14 (2018), 117–125.
Cinti, F., Moffa, S., Impronta, F., et al. Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date. Drug Des Devel Ther 11 (2017), 2905–2919.
Scheen, A.J., Paquot, N., Intérêt d'une combinaison agoniste des récepteurs du GLP-1 et insuline basale dans le traitement du diabète de type 2. Rev Med Suisse 10 (2014), 1549–1554.
Østergaard, L., Frandsen, C.S., Dejgaard, T.F., Madsbad, S., Fixed-ratio combination therapy with GLP-1 receptor agonist liraglutide and insulin degludec in people with type 2 diabetes. Expert Rev Clin Pharmacol 10 (2017), 621–632.
Scott, L.J., Insulin glargine/lixisenatide: a review in type 2 diabetes. Drugs 77 (2017), 1353–1362.
DeFronzo, R.A., Chilton, R., Norton, L., et al. Revitalization of pioglitazone: the optimal agent to be combined with a sodium-glucose cotransporter-2 inhibitor. Diabetes Obes Metab 18 (2016), 454–462.
Derosa, G., Sahebkar, A., Maffioli, P., The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice. J Cell Physiol 233 (2018), 153–161.
Wang, S., Dougherty, E.J., Danner, R.L., PPARγ signaling and emerging opportunities for improved therapeutics. Pharmacol Res 111 (2016), 76–85.
Thangavel, N., Al Bratty, M., Akhtar Javed, S., et al. Targeting peroxisome proliferator-activated receptors using thiazolidinediones: strategy for design of novel antidiabetic drugs. Int J Med Chem, 2017, 2017, 1069718.
Tan, C.K., Zhuang, Y., Wahli, W., Synthetic and natural Peroxisome Proliferator-Activated Receptor (PPAR) agonists as candidates for the therapy of the metabolic syndrome. Expert Opin Ther Targets 21 (2017), 333–348.
Colca, J.R., The TZD insulin sensitizer clue provides a new route into diabetes drug discovery. Expert Opin Drug Discov 10 (2015), 1259–1270.
Gross, B., Pawlak, M., Lefebvre, P., Staels, B., PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. Nat Rev Endocrinol 13 (2017), 36–49.
Lu, P., Zhao, Z., Advances on PPARγ research in the emerging era of precision medicine. Curr Drug Targets, 2017 Jun 21. doi: 10.2174/13894 50118666170622091333 [Epub ahead of print].
Scheen, A.J., GLP-1 receptor agonists and cardiovascular protection: A class effect or not ?. Diabetes Metab, 2018 Jan 6. doi.org/10.1016/j. diabet.2017.12.009 [Epub ahead of print].
Scheen, A.J., Semaglutide: a promising new glucagon-like peptide-1 receptor agonist. Lancet Diabetes Endocrinol 5 (2017), 236–238.
Dhillon, S., Semaglutide: first global approval. Drugs 78 (2018), 275–284.
Marso, S.P., Bain, S.C., Consoli, A., et al. SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375 (2016), 1834–1844.
Davies, M., Pieber, T.R., Hartoft-Nielsen, M.L., et al. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA 318 (2017), 1460–1470.
Davies, M.L., Thiman, M.L., Kugler, A.J., Efpeglenatide: a once-monthly GLP-1 RA in the pipeline. Austin J Endocrinol Diabetes, 3, 2016, 1053.
Henry, R., Rosenstock, J., McCarthy, J.F., et al. Treatment satisfaction with ITCA 650, a novel drug-device delivering continuous exenatide, versus twice-daily injections of exenatide in type 2 diabetics using metformin. Diabetes Obes Metab 20 (2018), 638–645.
Skow, M.A., Bergmann, N.C., Knop, F.K., Diabetes and obesity treatment based on dual incretin receptor activation: ‘twincretins’. Diabetes Obesity Metab 18 (2016), 847–854.
Frias, J.P., Bastyr, E.J. 3rd, Vignati, L., et al. The sustained effects of a dual GIP/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes. Cell Metab 26 (2017), 343–352 e2.
Schmitt, C., Portron, A., Jadidi, S., et al. Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus. Diabetes Obes Metab 19 (2017), 1436–1445.
Lefèbvre, P.J., Paquot, N., Scheen, A.J., Inhibiting or antagonizing glucagon: making progress in diabetes care. Diabetes Obes Metab 17 (2015), 720–725.
Scheen, A.J., Paquot, N., Obesity. A new paradigm for treating obesity and diabetes mellitus. Nat Rev Endocrinol 11 (2015), 196–198.
Finan, B., Yang, B., Ottaway, N., et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med 21 (2015), 27–36.
Scheen, A.J., Place des inhibiteurs des SGLT2 dans le traitement du patient diabétique de type 2. Maladies des maladies Métaboliques 12 (2018), 22–30.
Scheen, A.J., Ernest, P., Jandrain, B., Protection cardio-rénale par les inhibiteurs des SGLT2 (gliflozines) : d'EMPA-REG OUTCOME à CANVAS. Rev Med Suisse 13 (2017), 1421–1426.
Pratley, R.E., Eldor, R., Raji, A., et al. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial. Diabetes Obes Metab, 2017 Dec 21. doi: 10.1111/ dom.13194 [Epub ahead of print].
Ito, H., Shinozaki, M., Nishio, S., Abe, M., SGLT2 inhibitors in the pipeline for the treatment of diabetes mellitus in Japan. Expert Opin Pharmacother 17 (2016), 2073–2084.
Cariou, B., Charbonnel, B., Sotagliflozin as a potential treatment for type 2 diabetes mellitus. Expert Opin Investig Drugs 24 (2015), 1647–1656.
Garg, S.K., Henry, R.R., Banks, P., et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med 377 (2017), 2337–2348.
Scheen, A.J., GLP-1 receptor agonists or DPP-4 inhibitors: how to guide the clinician?. Ann Endocrinol (Paris) 74 (2013), 515–522.
Scheen, A.J., Once-weekly DPP-4 inhibitors: do they meet an unmet need?. Lancet Diabetes Endocrinol 3 (2015), 162–164.
Scheen, A.J., Investigational insulin secretagogues for type 2 diabetes. Expert Opin Investig Drugs 25 (2016), 405–422.
Pacini, G., Mari, A., Fouqueray, P., et al. Imeglimin increases glucose-dependent insulin secretion and improves β-cell function in patients with type 2 diabetes. Diabetes Obes Metab 17 (2015), 541–545.
Vuylsteke, V., Chastain, L.M., Maggu, G.A., Brown, C., Imeglimin: a potential new multi-target drug for type 2 diabetes. Drugs R D 15 (2015), 227–232.
Scheen, A.J., Paquot, N., Lefèbvre, P.J., Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes. Expert Opin Investig Drugs 26 (2017), 1373–1389.
Scheen, A.J., Van Gaal, L.F., Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. Lancet Diabetes Endocrinol 2 (2014), 911–922.
Van Gaal, L., Scheen, A., Weight management in type 2 diabetes: current and emerging approaches to treatment. Diabetes Care 38 (2015), 1161–1172.
Bessesen, D.H., Van Gaal, L.F., Progress and challenges in anti-obesity pharmacotherapy. Lancet Diabetes Endocrinol, 2017 Sep 14. pii: S2213-8587(17)30236-X. doi: 10.1016/S22138587(17)30236-X [Epub ahead of print].
Busch, R.S., Kane, M.P., Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes. Postgrad Med 129 (2017), 686–697.
Esser, N., Paquot, N., Scheen, A.J., Antiinflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease. Expert Opin Investig Drugs 24 (2015), 283–307.
Pollack, R.M., Donath, M.Y., LeRoith, D., Leibowitz, G., Anti-inflammatory agents in the treatment of diabetes and its vascular complications. Diabetes Care 39:Suppl.2 (2016), S244–S252.
Scheen, A.J., Esser, N., Paquot, N., Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control. Diabetes Metab 41 (2015), 183–194.
Peiró C., Lorenzo, Ó., Carraro, R., SánchezFerrer, C.F., IL-1β inhibition in cardiovascular complications associated to diabetes mellitus. Front Pharmacol, 8, 2017, 363.
Ridker, P.M., Everett, B.M., Thuren, T., et al. CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377 (2017), 1119–1131.
Tenenbaum, A., Fisman, E.Z., Mirroring the CANTOS revolution: is anti-inflammatory therapy for diabetes just around the corner?. Cardiovasc Diabetol, 16, 2017, 91.
Scheen, A.J., Precision medicine: The future in diabetes care ?. Diabetes Res Clin Pract 117 (2016), 12–21.
Florez, J.C., Pharmacogenetics in type 2 diabetes: precision medicine or discovery tool?. Diabetologia 60 (2017), 800–807.